Arrowhead moved a step closer to its aim of moving products into clinical trials.

Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its ...

The structure of Atalanta Therapeutics’ RNA interference drugs enables them to distribute broadly and deeply into brain tissue. Lead programs for Huntington’s disease and a rare inherited form ...

The hepatitis D market is expanding due to increased diagnosis rates and advancements in treatment options. Hepatitis D, a severe liver disease linked to hepatitis B virus (HBV) infection, is ...

Co-founded by RNA interference pioneer John Maraganore and former Medicines Company head Clive Meanwell, Corsera Health is ...

Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future of medicine. From CRISPR-based genome editing to new applications of in vivo and ex vivo cell therapies, scientific ...

The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Alan Herbert, InsideOutBio, discusses the significant advancements in RNA therapeutics, highlighting their role in supporting ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Source: Kidess GG, et al. Efficacy and safety of RNA interference therapeutics in patients with transthyretin amyloidosis cardiomyopathy. Presented at: American College of Cardiology Scientific ...

This Collection welcomes original research using RNA Interference, from genetic disorders to cancer, including methods and strategies on resolution and efficiency improvement.